Epogen

Generic Threats To Amgen's Biologics

Generic Threats To Amgen's Biologics

Seeking Alpha

[video]3 Amgen Biologics Facing Generic Competition

[video]3 Amgen Biologics Facing Generic Competition

Motley Fool

EPO Pills: A Challenge For Amgen And Johnson & Johnson

EPO Pills: A Challenge For Amgen And Johnson & Johnson

Seeking Alpha

Amgen's Epogen: Can This Blockbuster Drug Keep Shining?

Amgen's Epogen: Can This Blockbuster Drug Keep Shining?

Motley Fool

DaVita agrees to pay $55 million to settle suit over Epogen overuse

DaVita agrees to pay $55 million to settle suit over Epogen overuse

Yahoo/AP

Anemic Growth? Not From These Drugs.

Anemic Growth? Not From These Drugs.

Motley Fool

FDA OKs New Anemia Med That Challenges Amgen

FDA OKs New Anemia Med That Challenges Amgen

Pharmalot

Affymax rises on analyst view of anemia drug

Affymax rises on analyst view of anemia drug

Yahoo/AP

Amgen Says It Signed Seven-Year Epogen Sales Agreement With DaVita

Amgen Says It Signed Seven-Year Epogen Sales Agreement With DaVita

Bloomberg

Amgen and the Supremes: Did the CEO Know About a Kickback Scheme?

Amgen and the Supremes: Did the CEO Know About a Kickback Scheme?

BNET Pharma